Protocol Ledger

NCT03775109 · Phase II · COMPLETED

IL-1 Signal Inhibition in Alcoholic Hepatitis

Interventional Phase II clinical trial protocol NCT03775109 sponsored by Imperial College London in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-02-12 Enrollment: 55 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03775109
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)55 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03775109
Protocol FieldVerified Registry Value
NCT IdentifierNCT03775109
Consolidated Lead SponsorImperial College London
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment55 participants (ACTUAL)
Registered Start Date2019-02-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03775109
Hospital Research SiteLocationSite Profile
Queen Elizabeth University HospitalGlasgow, United KingdomOpen Hospital Dossier ->
King's College Hospital NHS Foundation TrustLondon, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI